What best means in this list
Best means the highest stored NexusTrade report ratings within this selection. Ratings use the product's 1-to-5 scale. The list sorts by rating from high to low, with ticker order breaking equal-rating ties. A rating summarizes a report; it does not predict a stock's return.
Companies belong to the Vaccines classification, based on company products and revenue. Classifications can overlap, so a company may appear in several industry lists.
Ratings and dated fundamentals
| 1 | ZOETIS INC. | ZTS | 4 | 2025-11-04 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $73.08 | $30,198,380,834.16 | 11.54 | 9.59 |
| 2 | Abbott Laboratories | ABT | 3.5 | 2025-10-15 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $98.49 | $170,425,450,823.04 | 31.41 | Not reported |
| 3 | Ligand Pharmaceuticals Inc. | LGND | 3.5 | 2025-11-06 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $295 | $5,881,004,655 | 29.82 | 6.08 |
| 4 | Merck & Co., Inc. | MRK | 3.5 | 2025-11-05 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $142.38 | $351,275,897,818.44 | 110.71 | Not reported |
| 5 | Thermo Fisher Scientific, Inc. | TMO | 3.5 | 2025-10-31 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $651.98 | $241,067,835,526.28 | 34.62 | Not reported |
| 6 | Pfizer Inc. | PFE | 3 | 2025-11-04 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $27.82 | $158,564,919,245.98 | 36.59 | 1.85 |
| 7 | Tarsus Pharmaceuticals, Inc. Common Stock | TARS | 3 | 2025-11-05 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $72.22 | $3,169,229,971.12 | Not reported | 9.14 |
| 8 | Elanco Animal Health Incorporated Common Stock | ELAN | 2.5 | 2025-11-05 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $22.54 | $11,261,476,048.2 | Not reported | 1.71 |
| 9 | IQVIA Holdings Inc. | IQV | 2.5 | 2025-10-30 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $258.88 | $42,611,648,000 | 30.99 | 6.76 |
| 10 | Phibro Animal Health Corporation Class A | PAHC | 2.5 | 2025-11-05 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $37.4 | $1,518,499,952.2 | 15.23 | 3.94 |
| 11 | Vaxcyte, Inc. Common Stock | PCVX | 2.5 | 2025-11-10 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $65.02 | $9,674,575,149.17 | Not reported | 3.51 |
| 12 | Prothena Corporation plc Ordinary Shares | PRTA | 2.5 | 2025-11-10 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $8.61 | $442,011,346.14 | Not reported | 1.54 |
| 13 | Sanofi American Depositary Shares (Each representing one-half of one ordinary share) | SNY | 2.5 | 2025-12-31 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $40.23 | $98,115,104,144.16 | 11.06 | Not reported |
| 14 | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | TAK | 2.5 | 2025-12-31 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $18.52 | $60,614,836,586.51 | Not reported | 1.29 |
| 15 | Arcturus Therapeutics Holdings Inc. Common Stock | ARCT | 2 | 2025-11-12 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $12.87 | $365,804,898.03 | Not reported | 2.13 |
| 16 | Emergent Biosolutions, Inc. | EBS | 2 | 2025-10-30 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $6.81 | $349,171,418.16 | Not reported | 1.02 |
| 17 | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | GSK | 2 | 2025-10-29 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $46.54 | $100,420,405,755.02 | 12.11 | 4.68 |
| 18 | Moderna, Inc. Common Stock | MRNA | 2 | 2025-10-30 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $197 | $78,649,470,133 | Not reported | 11.63 |
| 19 | Ocugen, Inc. Common Stock | OCGN | 2 | 2025-11-07 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $0.98 | $331,446,505.94 | Not reported | Not reported |
| 20 | Capricor Therapeutics Inc | CAPR | 1.5 | 2025-11-12 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $8.01 | $465,693,301.89 | Not reported | 1.89 |
| 21 | Fortress Biotech, Inc. | FBIO | 1.5 | 2025-11-14 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $2.09 | $69,620,015.08 | 0.62 | 0.34 |
| 22 | GeoVax Labs, Inc. New | GOVX | 1.5 | 2025-07-28 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $0.29 | $2,112,025.04 | Not reported | 1.2 |
| 23 | ImmunityBio, Inc. Common Stock | IBRX | 1.5 | 2025-11-07 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $9.91 | $10,502,977,465.43 | Not reported | Not reported |
| 24 | Novavax Inc | NVAX | 1.5 | 2025-11-06 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $11.01 | $1,816,052,443.26 | Not reported | Not reported |
| 25 | Opko Health Inc. | OPK | 1.5 | 2025-11-05 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $1.37 | $1,022,469,668.25 | Not reported | 0.86 |
| 26 | Oramed Pharmaceuticals Inc. | ORMP | 1.5 | 2025-11-14 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $4.2 | $174,708,886.8 | 1 | 0.55 |
| 27 | Vir Biotechnology, Inc. Common Stock | VIR | 1.5 | 2025-10-30 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $11.12 | $1,881,681,452.96 | Not reported | 1.92 |
| 28 | Agenus Inc. | AGEN | 1 | 2025-11-10 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $7.54 | $339,453,868.78 | 3.69 | Not reported |
| 29 | Alzamend Neuro, Inc. Common Stock | ALZN | 1 | 2025-09-10 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $1.34 | $6,466,468.82 | Not reported | 1.11 |
| 30 | Anixa Biosciences, Inc. | ANIX | 1 | 2025-09-25 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $2.91 | $101,162,663.82 | Not reported | 7.66 |
| 31 | Dyadic International, Inc. | DYAI | 1 | 2025-11-12 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $0.44 | $16,193,359.61 | Not reported | Not reported |
| 32 | Elicio Therapeutics, Inc. Common Stock | ELTX | 1 | 2025-08-07 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $1.81 | $47,570,206.42 | Not reported | 5.99 |
| 33 | Imunon, Inc. Common Stock | IMNN | 1 | 2025-11-17 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $1.07 | $6,004,201.21 | Not reported | 1.43 |
| 34 | Inovio Pharmaceuticals, Inc. | INO | 1 | 2025-11-11 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $1.09 | $112,703,294.62 | Not reported | 25.78 |
| 35 | Lunai Bioworks Inc. Common Stock | LNAI | 1 | 2025-11-17 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $1.12 | $5,077,956.8 | Not reported | Not reported |
| 36 | Matinas BioPharma Holdings, Inc. | MTNB | 1 | 2025-11-11 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $2.83 | $1,208,633.57 | Not reported | 0.67 |
| 37 | NextPlat Corp Common Stock | NXPL | 1 | 2025-11-13 | 2025 FY | google/gemini-2.5-flash-lite | 2026-10-08 | $9.15 | $24,825,981.3 | Not reported | 1.51 |
| 38 | PDS Biotechnology Corporation Common Stock | PDSB | 1 | 2025-11-13 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $1.02 | $57,090,764.76 | Not reported | Not reported |
| 39 | Precigen, Inc. Common Stock | PGEN | 1 | 2025-11-13 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $7.6 | $2,721,067,877.2 | Not reported | 62.44 |
| 40 | Serina Therapeutics, Inc. | SER | 1 | 2025-11-13 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $2.01 | $51,054,950.73 | Not reported | 2.73 |
| 41 | Sutro Biopharma, Inc. | STRO | 1 | 2025-11-06 | 2025 FY | google/gemini-2.5-flash | 2026-10-08 | $15.32 | $254,023,539.72 | Not reported | Not reported |
No matching rows. Clear the filter to see all records.
41 companies with eligible ratings and dated fundamentals, from 61 eligible companies in this selection.
Dates and coverage
Report dates range from 2025-07-28 to 2025-12-31. Market observations range from 2026-10-08 to 2026-10-08. These dates may differ across companies. Daily closes are not synchronized live quotes.
The selection includes 19 companies without a report, 0 with invalid latest rating metadata, 0 with older reports, 1 with missing required fundamentals and 0 with out-of-date market observations. Missing companies receive no substitute score.
How the ranking is built
The ranking uses the latest stored report at or before the refresh cutoff for each active eligible company. The report date, fiscal year/period and producing model remain visible. The latest invalid score is excluded; an older favorable score does not replace it. Publication policy stock-ratings-v1 accepts report ages up to 550 days and market observations up to 10 calendar days, with a positive close and market capitalization. Optional missing ratios remain not reported.
Report ages can differ substantially, particularly between annual and quarterly reports. Different producing models may also use different judgments. Read the date, fiscal period and model before comparing scores. Private report analysis and account data are not published here.
A refresh reads existing reports and market data. It does not rerun a model or create a new analysis. Compare business fundamentals and your own research constraints alongside the score before making a decision.